(Q54075751)

24 May 2018

title

Topoisomerase II-mediated alterations of K562 drug resistant sublines. (English)

1 reference

24 May 2018

4

R Larsson

1 reference

24 May 2018

R Zhou

1

1 reference

24 May 2018

Y Wang

2

1 reference

24 May 2018

A Gruber

3

1 reference

24 May 2018

E Castaños-Vèlez

5

1 reference

24 May 2018

E Liliemark

6

1 reference

24 May 2018

publication date

1 September 1999

1 reference

24 May 2018

published in

Medical Oncology

1 reference

24 May 2018

volume

16

1 reference

24 May 2018

issue

3

1 reference

24 May 2018

page(s)

191-198

1 reference

24 May 2018

https://scigraph.springernature.com/pub.10.1007/bf02906131

exact match

0 references

cites work

Topoisomerase-targeting antitumor drugs

1 reference

12 December 2020

Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24

1 reference

12 December 2020

Multidrug resistance gene (mdr1) RNA levels in relation to P-glycoprotein content of leukemic cells from patients with acute leukemia.

1 reference

12 December 2020

Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.

1 reference

12 December 2020

DNA topoisomerase poisons as antitumor drugs

1 reference

12 December 2020

The 180-kDa isoform of topoisomerase II is localized in the nucleolus and belongs to the structural elements of the nucleolar remnant

1 reference

12 December 2020

Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.

1 reference

12 December 2020

Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells

1 reference

12 December 2020

DNA damage induced by etoposide; a comparison of two different methods for determination of strand breaks in DNA.

1 reference

12 December 2020

Mitotic chromatin condensation in vitro using somatic cell extracts and nuclei with variable levels of endogenous topoisomerase II.

1 reference

12 December 2020

Etoposide-induced DNA strand breaks in relation to p-glycoprotein and topoisomerase II protein expression in leukaemic cells from patients with AML and CLL

1 reference

12 December 2020

Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22

1 reference

12 December 2020

Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.

1 reference

12 December 2020

Protein measurement with the Folin phenol reagent

1 reference

12 December 2020

Etoposide dosage and pharmacodynamics

1 reference

12 December 2020

Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26

1 reference

12 December 2020

Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA)

1 reference

12 December 2020

DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors

1 reference

12 December 2020

DNA topoisomerase dysfunction: a new goal for antitumor chemotherapy

1 reference

12 December 2020

Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02906131

1 reference

24 May 2018

1 reference

24 May 2018